Biomedical Engineering Reference
In-Depth Information
43. Sebille S, de Tullio P, Becker B et al (2005) 4,6-Disubstituted 2,2-dimethylchromans struc-
turally related to the K(ATP) channel opener cromakalim: design, synthesis, and effect on
insulin release and vascular tone. J Med Chem 48:614-621
44. Sharma S, Prabhakar YS, Singh P et al (2008) QSAR study about ATP-sensitive potassium
channel activation of cromakalim analogues using CP-MLR approach. Eur J Med Chem
43:2354-2360
45. Gerlach U, Brendel J, Lang H-J et al (2001) Synthesis and activity of novel and selective IKs-
channel blockers. J Med Chem 44:3831-3837
46. Satuluri VSAK, Seelam J, Gupta SP (2008) A quantitative structure-activity relationship study
on some series of potassium channel blockers. Med Chem 5:87-92
47. Atwal KS, Grover GJ, Ahmed SZ et al (1993) Cardioselective anti-ischemic ATP-sensitive
potassium channel openers. J Med Chem 36:3971-3974
48. Rovnyak GC, Ahmed SZ, Ding CZ et al (1997) Cardioselective antiischemic ATP-sensitive
potassium channel (K
ATP
) openers. 5. Identification of 4-(N-aryl)-substituted benzopyran
derivatives with high selectivity. J Med Chem 40:24-34
49. Satuluri VSAK, Gupta SP (2008) A QSAR study on some series of ATP-sensitive potassium
channel openers. Lett Drug Des Discov 5:173-177
50. Cecchetti V, Calderone V, Tabarrini O et al (2003) Highly potent 1,4-benzothiazine
derivatives as K (ATP)-channel openers. J Med Chem 46:3670-3679
51. Carosati E, Lemoine H, Spogli R et al (2005) Binding studies and GRIND/ALMOND-based 3D
QSAR analysis of benzothiazine type K
ATP
-channel openers. Bioorg Med Chem 13:5581-5591
52. Pastor M, Cruciani G, McLay I et al (2000) GRid-INdependent descriptors (GRIND): a novel
class of alignment-independent
three-dimensional molecular descriptors. J Med Chem
43:3233-3243
53. de Tullio P, Boverie S, Becker B et al (2005) 3-Alkylamino-4H-1,2,4-benzothiadiazine
1,1-dioxides as ATP-sensitive potassium channel openers: effect of 6,7-disubstitution on
potency and tissue selectivity. J Med Chem 48:4990-5000
54. de Tullio P, Becker B, Boverie S et al (2003) Toward tissue-selective pancreatic B-cells K
ATP
channel openers belonging to 3-alkylamino-7-halo-4
H
-1,2,4-benzothiadiazine 1,1-dioxides.
J Med Chem 46:3342-3353
55. Boverie S, Antoine M-H, Somers F et al (2005) Effect on K(ATP) channel activation
properties and tissue selectivity of the nature of the substituent in the 7-and the 3-position
of 4
H
-1,2,4-benzothiadiazine 1,1-dioxides. J Med Chem 48:3492-3503
56. Sharma BK, Sharma SK, Singh P et al (2008) Quantitative structure-activity relationship
study of ATP-sensitive potassium channel openers: derivatives of 3-alkylamino-4
H
-1,2,
4-benzothiadiazine 1,1-dioxide. J Enzyme Inhib Med Chem 23:1-6
57. Sharma BK, Sharma SK, Pilania P et al (2009) A quantitative structure-activity relationship
study of ATP-sensitive potassium channel openers: the derivatives of 3-alkylamino-4
H
-1,2,
4-benzothiadiazine 1,1-dioxide. Int J Chem Sci 7:655-671
58. Wulff H, Calabresi PA, Allie R et al (2003) The voltage-gated Kv1.3 K
+
channel in effector
memory T cells as new target for MS. J Clin Invest 111:1703-1713
59. Beeton C, Barbaria J, Giraud P et al (2001) Selective blocking of voltage-gated K
+
channels
improves experimental autoimmune encephalomyelitis and inhibits T cell activation.
J Immunol 166:936-944
60. Beeton C, Wulff H, Barbaria J et al (2001) Selective blockade of T lymphocyte K
+
channels
ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc
Natl Acad Sci USA 98:13942-13947
61. Baell JB, Gable RW, Harvey AJ et al (2004) Khellinone derivatives as blockers of voltage-
gated potassium channel Kvl.3: synthesis and immunosuppressive activity. J Med Chem
47:2326-2336
62. Harvey AJ, Baell JB, Toovey N et al (2006) A new class of blockers of the voltage-gated
potassium channel Kv1.3 via modification of the 4- or 7-position of khellinone. J Med Chem
49:1433-1441
